GYKI-47261 dihydrochloride is a selective AMPA receptor antagonist, administered orally, and exhibits competitive activity with an IC 50 of 2.5 μM. It displays a wide range of anticonvulsive effects and demonstrates neuroprotective properties. Additionally, GYKI-47261 dihydrochloride is a potent inducer of CYP2E1.

GYKI-47261 dihydrochloride (6 mg/kg; i.v.) shows antiischemice effect in a transient focal ischemia model, in rats. GYKI-47261 dihydrochloride (p.o.) potently mitigated the tremor induced by oxotremorine with ED50 of 16.8 mg/kg in male CD1 mice[1]. GYKI-47261 dihydrochloride(20 mg/kg; i.p.) reverses the dopamine depleting effect of MPTP[1]. Animal Model: Male C57 black mice, weighing 23-30 g[1]Dosage: 20 mg/kg Administration: I.p. Result: Reversed the MPTP-induced decrease in striatal concentrations.